Opioid Use Disorder Market Size, Share and Growth Outlook 2026: By Drug (Buprenorphine, Methadone, Naltrexone), By Route of Administration, By Distribution Channel, Companies to 2034.
The global Opioid Use Disorder Market size is forecast to increase from $6.02 Billion in 2026 to $13.76 Billion in 2034 at a CAGR of 10.89% between 2026 and 2034.
The Opioid Use Disorder market report provides detailed analysis and outlook of Opioid Use Disorder segments including By Drug (Buprenorphine, Methadone, Naltrexone), By Route of Administration (Oral Administration, Injectable Administration, Transdermal / Subdermal Implants and Patches), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Government / Public Health Clinics and Rehabilitation Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Opioid Use Disorder Industry Overview
Policy Expansion, Long-Acting Therapies, and Evidence-Based Care Models Are Transforming Opioid Use Disorder Treatment
The opioid use disorder (OUD) industry is undergoing substantial transformation as healthcare systems, regulators, and policymakers increasingly prioritize evidence-based treatment models, expanded medication access, and long-acting therapeutic approaches. The market is shifting beyond acute detoxification and short-term treatment strategies toward chronic disease management frameworks that emphasize sustained recovery, overdose prevention, and reduced healthcare utilization. Regulatory reforms, reimbursement expansion, and growing acceptance of medications for opioid use disorder (MOUD) are accelerating adoption across healthcare systems, behavioral health programs, and community treatment settings. At the same time, pharmaceutical innovation continues to focus on improving treatment adherence, reducing barriers to care initiation, and expanding access to long-acting formulations.
Long-Acting Buprenorphine Therapies Are Reshaping Treatment Delivery Models
Extended-release formulations have emerged as a critical advancement in opioid use disorder treatment by addressing challenges related to medication adherence, diversion risks, and treatment retention. Healthcare providers increasingly favor long-acting therapeutic approaches capable of supporting sustained recovery while reducing the burden associated with daily dosing regimens. This trend was reinforced by the U.S. FDA approval of updated labeling for Sublocade, the extended-release buprenorphine injection developed by Indivior. The regulatory update expanded approved administration sites beyond the abdomen to include the thigh, buttock, and upper arm while significantly simplifying treatment initiation protocols by reducing induction requirements from a seven-day transmucosal regimen to a single buprenorphine dose followed by a one-hour observation period. These modifications represent an important step toward improving treatment accessibility and accelerating patient entry into medication-assisted recovery programs.
Federal Policy Support Is Expanding Access to Medication-Assisted Treatment
Government agencies increasingly recognize opioid use disorder as a chronic medical condition requiring evidence-based pharmacological interventions integrated within broader social and healthcare support systems. Expanded reimbursement mechanisms and federal funding initiatives are strengthening access to proven treatment modalities across underserved populations. This shift was highlighted by the decision of the U.S. Department of Health and Human Services Administration for Children and Families to designate buprenorphine, methadone, and naltrexone as eligible evidence-based interventions under Title IV-E Prevention Services funding frameworks. The policy enables states, tribal organizations, and U.S. territories to access federal matching funds for delivering medication-assisted opioid treatment within child welfare prevention programs. Such policy developments reflect the growing institutional acceptance of medications for opioid use disorder as essential components of public health and family preservation strategies.
Real-World Evidence Is Reinforcing the Clinical Value of Extended-Release Therapies
Large-scale observational datasets are increasingly influencing treatment guidelines, reimbursement decisions, and healthcare system adoption of opioid use disorder therapies. Real-world evidence has become particularly important for evaluating long-term outcomes, healthcare resource utilization, and overdose prevention strategies. Data presented at the American Society of Addiction Medicine Annual Conference demonstrated that monthly extended-release buprenorphine treatment was associated with the lowest rates of fatal and non-fatal overdose events among more than 500,000 patient treatment records analyzed. Additionally, patients receiving extended-release buprenorphine experienced reduced healthcare utilization, including lower rates of serious complications such as bacteremia, compared with individuals receiving standard daily oral therapies or no treatment. These findings further support the expanding role of long-acting medications as foundational components of contemporary opioid use disorder management strategies.
Opioid Use Disorder Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Opioid Use Disorder market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Indivior PLC, Alkermes plc, Orexo AB, Camurus AB, Titan Pharmaceuticals, Inc., Mallinckrodt plc, Hikma Pharmaceuticals PLC, Viatris Inc., BioDelivery Sciences International Inc. (Collegium Pharmaceutical), Braeburn Pharmaceuticals, Inc.. The Opioid Use Disorder market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Opioid Use Disorder industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Opioid Use Disorder industry include- Indivior PLC, Alkermes plc, Orexo AB, Camurus AB, Titan Pharmaceuticals, Inc., Mallinckrodt plc, Hikma Pharmaceuticals PLC, Viatris Inc., BioDelivery Sciences International Inc. (Collegium Pharmaceutical), Braeburn Pharmaceuticals, Inc.. The Opioid Use Disorder market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Opioid Use Disorder Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Opioid Use Disorder market remains one of the strongest-performing segments in the country.
The US Opioid Use Disorder Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Opioid Use Disorder market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Opioid Use Disorder industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Opioid Use Disorder markets
Canada's strong Opioid Use Disorder sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Opioid Use Disorder market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Opioid Use Disorder Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Opioid Use Disorder market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Opioid Use Disorder population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Opioid Use Disorder industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Opioid Use Disorder market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Opioid Use Disorder sales through 2034
France Opioid Use Disorder companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Opioid Use Disorder Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Opioid Use Disorder distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Opioid Use Disorder Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Opioid Use Disorder market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Opioid Use Disorder industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Opioid Use Disorder industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Opioid Use Disorder Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Opioid Use Disorder market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Opioid Use Disorder market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Opioid Use Disorder Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Opioid Use Disorder Market Segmentation
By Drug
Buprenorphine
Methadone
Naltrexone
By Route of Administration
Oral Administration
Injectable Administration
Transdermal / Subdermal Implants and Patches
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Government / Public Health Clinics and Rehabilitation Centers
Leading Companies in Opioid Use Disorder Industry (2026)
Indivior PLC
Alkermes plc
Orexo AB
Camurus AB
Titan Pharmaceuticals, Inc.
Mallinckrodt plc
Hikma Pharmaceuticals PLC
Viatris Inc.
BioDelivery Sciences International Inc. (Collegium Pharmaceutical)
Braeburn Pharmaceuticals, Inc.
Countries Included
The Opioid Use Disorder market report provides detailed analysis and outlook of Opioid Use Disorder segments including By Drug (Buprenorphine, Methadone, Naltrexone), By Route of Administration (Oral Administration, Injectable Administration, Transdermal / Subdermal Implants and Patches), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Government / Public Health Clinics and Rehabilitation Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Opioid Use Disorder Industry Overview
Policy Expansion, Long-Acting Therapies, and Evidence-Based Care Models Are Transforming Opioid Use Disorder Treatment
The opioid use disorder (OUD) industry is undergoing substantial transformation as healthcare systems, regulators, and policymakers increasingly prioritize evidence-based treatment models, expanded medication access, and long-acting therapeutic approaches. The market is shifting beyond acute detoxification and short-term treatment strategies toward chronic disease management frameworks that emphasize sustained recovery, overdose prevention, and reduced healthcare utilization. Regulatory reforms, reimbursement expansion, and growing acceptance of medications for opioid use disorder (MOUD) are accelerating adoption across healthcare systems, behavioral health programs, and community treatment settings. At the same time, pharmaceutical innovation continues to focus on improving treatment adherence, reducing barriers to care initiation, and expanding access to long-acting formulations.
Long-Acting Buprenorphine Therapies Are Reshaping Treatment Delivery Models
Extended-release formulations have emerged as a critical advancement in opioid use disorder treatment by addressing challenges related to medication adherence, diversion risks, and treatment retention. Healthcare providers increasingly favor long-acting therapeutic approaches capable of supporting sustained recovery while reducing the burden associated with daily dosing regimens. This trend was reinforced by the U.S. FDA approval of updated labeling for Sublocade, the extended-release buprenorphine injection developed by Indivior. The regulatory update expanded approved administration sites beyond the abdomen to include the thigh, buttock, and upper arm while significantly simplifying treatment initiation protocols by reducing induction requirements from a seven-day transmucosal regimen to a single buprenorphine dose followed by a one-hour observation period. These modifications represent an important step toward improving treatment accessibility and accelerating patient entry into medication-assisted recovery programs.
Federal Policy Support Is Expanding Access to Medication-Assisted Treatment
Government agencies increasingly recognize opioid use disorder as a chronic medical condition requiring evidence-based pharmacological interventions integrated within broader social and healthcare support systems. Expanded reimbursement mechanisms and federal funding initiatives are strengthening access to proven treatment modalities across underserved populations. This shift was highlighted by the decision of the U.S. Department of Health and Human Services Administration for Children and Families to designate buprenorphine, methadone, and naltrexone as eligible evidence-based interventions under Title IV-E Prevention Services funding frameworks. The policy enables states, tribal organizations, and U.S. territories to access federal matching funds for delivering medication-assisted opioid treatment within child welfare prevention programs. Such policy developments reflect the growing institutional acceptance of medications for opioid use disorder as essential components of public health and family preservation strategies.
Real-World Evidence Is Reinforcing the Clinical Value of Extended-Release Therapies
Large-scale observational datasets are increasingly influencing treatment guidelines, reimbursement decisions, and healthcare system adoption of opioid use disorder therapies. Real-world evidence has become particularly important for evaluating long-term outcomes, healthcare resource utilization, and overdose prevention strategies. Data presented at the American Society of Addiction Medicine Annual Conference demonstrated that monthly extended-release buprenorphine treatment was associated with the lowest rates of fatal and non-fatal overdose events among more than 500,000 patient treatment records analyzed. Additionally, patients receiving extended-release buprenorphine experienced reduced healthcare utilization, including lower rates of serious complications such as bacteremia, compared with individuals receiving standard daily oral therapies or no treatment. These findings further support the expanding role of long-acting medications as foundational components of contemporary opioid use disorder management strategies.
Opioid Use Disorder Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Opioid Use Disorder market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Indivior PLC, Alkermes plc, Orexo AB, Camurus AB, Titan Pharmaceuticals, Inc., Mallinckrodt plc, Hikma Pharmaceuticals PLC, Viatris Inc., BioDelivery Sciences International Inc. (Collegium Pharmaceutical), Braeburn Pharmaceuticals, Inc.. The Opioid Use Disorder market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Opioid Use Disorder industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Opioid Use Disorder Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Opioid Use Disorder companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Opioid Use Disorder markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Opioid Use Disorder industry include- Indivior PLC, Alkermes plc, Orexo AB, Camurus AB, Titan Pharmaceuticals, Inc., Mallinckrodt plc, Hikma Pharmaceuticals PLC, Viatris Inc., BioDelivery Sciences International Inc. (Collegium Pharmaceutical), Braeburn Pharmaceuticals, Inc.. The Opioid Use Disorder market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Opioid Use Disorder Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Opioid Use Disorder market remains one of the strongest-performing segments in the country.
The US Opioid Use Disorder Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Opioid Use Disorder market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Opioid Use Disorder industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Opioid Use Disorder markets
Canada's strong Opioid Use Disorder sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Opioid Use Disorder market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Opioid Use Disorder Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Opioid Use Disorder market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Opioid Use Disorder population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Opioid Use Disorder industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Opioid Use Disorder market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Opioid Use Disorder sales through 2034
France Opioid Use Disorder companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Opioid Use Disorder Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Opioid Use Disorder distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Opioid Use Disorder Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Opioid Use Disorder market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Opioid Use Disorder industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Opioid Use Disorder industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Opioid Use Disorder Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Opioid Use Disorder market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Opioid Use Disorder market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Opioid Use Disorder Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Opioid Use Disorder Market Segmentation
By Drug
Buprenorphine
Methadone
Naltrexone
By Route of Administration
Oral Administration
Injectable Administration
Transdermal / Subdermal Implants and Patches
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Government / Public Health Clinics and Rehabilitation Centers
Leading Companies in Opioid Use Disorder Industry (2026)
Indivior PLC
Alkermes plc
Orexo AB
Camurus AB
Titan Pharmaceuticals, Inc.
Mallinckrodt plc
Hikma Pharmaceuticals PLC
Viatris Inc.
BioDelivery Sciences International Inc. (Collegium Pharmaceutical)
Braeburn Pharmaceuticals, Inc.
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Opioid Use Disorder Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Opioid Use Disorder Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL OPIOID USE DISORDER MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Opioid Use Disorder Markets in 2026
3.2. Global Historic and Forecast Opioid Use Disorder Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Opioid Use Disorder Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Opioid Use Disorder Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Opioid Use Disorder Value Chain
CHAPTER 4- OPIOID USE DISORDER MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Opioid Use Disorder Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- OPIOID USE DISORDER MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Drug
Buprenorphine
Methadone
Naltrexone
By Route of Administration
Oral Administration
Injectable Administration
Transdermal / Subdermal Implants and Patches
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Government / Public Health Clinics and Rehabilitation Centers
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA OPIOID USE DISORDER MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Opioid Use Disorder Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Opioid Use Disorder Market Trends and Growth Opportunities to 2034
7.5. North America Opioid Use Disorder Market Size Outlook by Type
7.6. North America Opioid Use Disorder Market Size Outlook by Application
7.7. North America Opioid Use Disorder Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Opioid Use Disorder Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Opioid Use Disorder Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Opioid Use Disorder Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Opioid Use Disorder Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Opioid Use Disorder Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Opioid Use Disorder Companies
CHAPTER 8- EUROPE OPIOID USE DISORDER MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Opioid Use Disorder Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Opioid Use Disorder Market Trends and Growth Opportunities to 2034
8.5. Europe Opioid Use Disorder Market Size Outlook by Type
8.6. Europe Opioid Use Disorder Market Size Outlook by Application
8.7. Europe Opioid Use Disorder Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Opioid Use Disorder Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Opioid Use Disorder Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Opioid Use Disorder Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Opioid Use Disorder Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Opioid Use Disorder Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Opioid Use Disorder Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Opioid Use Disorder Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Opioid Use Disorder Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Opioid Use Disorder Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Opioid Use Disorder Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Opioid Use Disorder Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Opioid Use Disorder Companies
CHAPTER 9- ASIA PACIFIC OPIOID USE DISORDER MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Opioid Use Disorder Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Opioid Use Disorder Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Opioid Use Disorder Market Size Outlook by Type
9.6. Asia Pacific Opioid Use Disorder Market Size Outlook by Application
9.7. Asia Pacific Opioid Use Disorder Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Opioid Use Disorder Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Opioid Use Disorder Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Opioid Use Disorder Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Opioid Use Disorder Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Opioid Use Disorder Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Opioid Use Disorder Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Opioid Use Disorder Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Opioid Use Disorder Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Opioid Use Disorder Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Opioid Use Disorder Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Opioid Use Disorder Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Opioid Use Disorder Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA OPIOID USE DISORDER MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Opioid Use Disorder Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Opioid Use Disorder Market Trends and Growth Opportunities to 2034
10.5. South and Central America Opioid Use Disorder Market Size Outlook by Type
10.6. South and Central America Opioid Use Disorder Market Size Outlook by Application
10.7. South and Central America Opioid Use Disorder Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Opioid Use Disorder Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Opioid Use Disorder Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Opioid Use Disorder Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Opioid Use Disorder Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Opioid Use Disorder Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Opioid Use Disorder Companies
CHAPTER 11- MIDDLE EAST AND AFRICA OPIOID USE DISORDER MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Opioid Use Disorder Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Opioid Use Disorder Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Opioid Use Disorder Market Size Outlook by Type
11.6. Middle East and Africa Opioid Use Disorder Market Size Outlook by Application
11.7. Middle East and Africa Opioid Use Disorder Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Opioid Use Disorder Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Opioid Use Disorder Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Opioid Use Disorder Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Opioid Use Disorder Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Opioid Use Disorder Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Opioid Use Disorder Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Opioid Use Disorder Industry
Indivior PLC
Alkermes plc
Orexo AB
Camurus AB
Titan Pharmaceuticals, Inc.
Mallinckrodt plc
Hikma Pharmaceuticals PLC
Viatris Inc.
BioDelivery Sciences International Inc. (Collegium Pharmaceutical)
Braeburn Pharmaceuticals, Inc.
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Opioid Use Disorder Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Opioid Use Disorder Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL OPIOID USE DISORDER MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Opioid Use Disorder Markets in 2026
3.2. Global Historic and Forecast Opioid Use Disorder Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Opioid Use Disorder Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Opioid Use Disorder Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Opioid Use Disorder Value Chain
CHAPTER 4- OPIOID USE DISORDER MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Opioid Use Disorder Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- OPIOID USE DISORDER MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Drug
Buprenorphine
Methadone
Naltrexone
By Route of Administration
Oral Administration
Injectable Administration
Transdermal / Subdermal Implants and Patches
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Government / Public Health Clinics and Rehabilitation Centers
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA OPIOID USE DISORDER MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Opioid Use Disorder Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Opioid Use Disorder Market Trends and Growth Opportunities to 2034
7.5. North America Opioid Use Disorder Market Size Outlook by Type
7.6. North America Opioid Use Disorder Market Size Outlook by Application
7.7. North America Opioid Use Disorder Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Opioid Use Disorder Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Opioid Use Disorder Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Opioid Use Disorder Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Opioid Use Disorder Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Opioid Use Disorder Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Opioid Use Disorder Companies
CHAPTER 8- EUROPE OPIOID USE DISORDER MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Opioid Use Disorder Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Opioid Use Disorder Market Trends and Growth Opportunities to 2034
8.5. Europe Opioid Use Disorder Market Size Outlook by Type
8.6. Europe Opioid Use Disorder Market Size Outlook by Application
8.7. Europe Opioid Use Disorder Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Opioid Use Disorder Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Opioid Use Disorder Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Opioid Use Disorder Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Opioid Use Disorder Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Opioid Use Disorder Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Opioid Use Disorder Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Opioid Use Disorder Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Opioid Use Disorder Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Opioid Use Disorder Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Opioid Use Disorder Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Opioid Use Disorder Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Opioid Use Disorder Companies
CHAPTER 9- ASIA PACIFIC OPIOID USE DISORDER MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Opioid Use Disorder Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Opioid Use Disorder Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Opioid Use Disorder Market Size Outlook by Type
9.6. Asia Pacific Opioid Use Disorder Market Size Outlook by Application
9.7. Asia Pacific Opioid Use Disorder Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Opioid Use Disorder Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Opioid Use Disorder Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Opioid Use Disorder Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Opioid Use Disorder Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Opioid Use Disorder Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Opioid Use Disorder Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Opioid Use Disorder Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Opioid Use Disorder Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Opioid Use Disorder Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Opioid Use Disorder Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Opioid Use Disorder Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Opioid Use Disorder Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA OPIOID USE DISORDER MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Opioid Use Disorder Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Opioid Use Disorder Market Trends and Growth Opportunities to 2034
10.5. South and Central America Opioid Use Disorder Market Size Outlook by Type
10.6. South and Central America Opioid Use Disorder Market Size Outlook by Application
10.7. South and Central America Opioid Use Disorder Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Opioid Use Disorder Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Opioid Use Disorder Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Opioid Use Disorder Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Opioid Use Disorder Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Opioid Use Disorder Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Opioid Use Disorder Companies
CHAPTER 11- MIDDLE EAST AND AFRICA OPIOID USE DISORDER MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Opioid Use Disorder Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Opioid Use Disorder Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Opioid Use Disorder Market Size Outlook by Type
11.6. Middle East and Africa Opioid Use Disorder Market Size Outlook by Application
11.7. Middle East and Africa Opioid Use Disorder Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Opioid Use Disorder Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Opioid Use Disorder Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Opioid Use Disorder Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Opioid Use Disorder Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Opioid Use Disorder Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Opioid Use Disorder Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Opioid Use Disorder Industry
Indivior PLC
Alkermes plc
Orexo AB
Camurus AB
Titan Pharmaceuticals, Inc.
Mallinckrodt plc
Hikma Pharmaceuticals PLC
Viatris Inc.
BioDelivery Sciences International Inc. (Collegium Pharmaceutical)
Braeburn Pharmaceuticals, Inc.
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
